The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?
This webinar will explain how pricing has evolved for the rare disease drug market and…
webdev2020年2月19日
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
Certara2019年12月19日
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…
Certara2019年10月24日
Innovative Solutions for Fast-Tracking Drugs for Rare Diseases
This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…
webdev2019年8月10日
Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement
This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…
webdev2019年5月13日
Trends for Market Access, HEOR, and Real World Evidence
This blog reviews trends for using health economics and outcomes research and real-world evidence to…
Certara2019年5月10日
Real World Evidence Marches Forward in Drug Development
The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…
Certara2019年3月20日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…
Jieun Choe2018年6月2日
